CIK 0000949858 · In Vitro & In Vivo Diagnostic Substances (SIC 2835) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | ||||
| Net income (USD) | -42.4 M | -33.2 M | -14.7 M | |
| Diluted EPS (USD/shares) | -1.25 | -4 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-06 | 4 | 4 | 2026-10-05 |
| 2026-10-06 | 3 | 3 | 2026-10-05 |
| 2026-10-01 | 8-K | 8-K items 5.02 | 2026-10-01 |
| 2026-08-21 | 4 | 4 | 2026-08-19 |
| 2026-08-19 | 144 | 144 | |
| 2026-08-17 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-14 | 8-K | 8-K items 8.01,9.01 | 2026-08-14 |
| 2026-08-14 | 424B5 | 424B5 | |
| 2026-08-13 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,9.01 | 2026-08-11 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-28 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-08 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-06 | 8-K | 8-K items 5.03,5.07,9.01 | 2026-07-02 |
| 2026-06-08 | ARS | ARS | 2025-12-31 |
| 2026-06-08 | DEF 14A | DEF 14A | 2026-06-08 |
| 2026-06-02 | 4 | 4 | 2026-05-29 |
Forms on file (last 1,000): 4 311, 8-K 202, SC 13G/A 57, 10-Q 53, CORRESP 39, 3 36, SC 13G 32, UPLOAD 25. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ACHV (0.002 USD), /gw/filings/filings?ticker=ACHV&form=8-K, /gw/filings/facts?ticker=ACHV&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange